Last reviewed · How we verify

LCP-tacrolimus QD + MMF BID — Competitive Intelligence Brief

LCP-tacrolimus QD + MMF BID (LCP-tacrolimus QD + MMF BID) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcineurin inhibitor + antimetabolite combination. Area: Immunology / Transplantation.

marketed Calcineurin inhibitor + antimetabolite combination Calcineurin (tacrolimus); IMPDH type II (mycophenolate mofetil) Immunology / Transplantation Small molecule Live · refreshed every 30 min

Target snapshot

LCP-tacrolimus QD + MMF BID (LCP-tacrolimus QD + MMF BID) — University Hospital, Limoges. LCP-tacrolimus is a prolonged-release formulation of tacrolimus combined with mycophenolate mofetil (MMF) to suppress T-cell mediated immune responses and prevent organ rejection.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
LCP-tacrolimus QD + MMF BID TARGET LCP-tacrolimus QD + MMF BID University Hospital, Limoges marketed Calcineurin inhibitor + antimetabolite combination Calcineurin (tacrolimus); IMPDH type II (mycophenolate mofetil)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcineurin inhibitor + antimetabolite combination class)

  1. University Hospital, Limoges · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LCP-tacrolimus QD + MMF BID — Competitive Intelligence Brief. https://druglandscape.com/ci/lcp-tacrolimus-qd-mmf-bid. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: